Kleresca® strengthens scientific proof of fluorescent light energy (FLE) in new study
In a recent, peer-reviewed study, Kleresca® presents documentation that its unique FLE technology is able to reduce inflammation in the skin, enhance collagen production, and encourage the development of new blood vessels.
The study investigated the cellular mode of action of FLE (fluorescent light energy) on skin and immune cells and combined clinical results with laboratory studies. This approach offered a unique opportunity to provide scientific answers to specific clinical questions.
The study results show how FLE reduces inflammation in the skin, enhances collagen production, and stimulates angiogenesis (the development of new blood vessels). While further research is required to fully elucidate the mode of action of FLE, the findings have important implications for Kleresca® with regards to treating inflammatory skin conditions going forward.
“These new findings are a milestone for Kleresca® as they strongly support our current range of products including FLE for acne, rosacea and skin rejuvenation and provide strong hints towards new therapeutic areas for Kleresca®”, says Kleresca® General Manager Mr. Mikkel Schoedt.
Therapeutic areas like actinic keratosis (solar keratosis), psoriasis and atopic dermatitis (eczema) are considered for the future clinical pathway for Kleresca®. As the FLE technology is painless with no serious side effects, it is considered a promising alternative to current standard treatments.
The investigative study was conducted by Kleresca® in collaboration with the University of Copenhagen, The technical University of Denmark, the University of Molise in Campobasso, Italy as well as Klox Technologies, Canada.
The study was peer-reviewed and published in the Journal of Clinical and Aesthetic dermatology.
At Kleresca®, we aspire to change the fundamentals of dermatology. Our innovative biophotonic technology represents a unique mode of action that allows us to create a new gold standard within the industry for the benefit of patients worldwide. The Kleresca® biophotonic platform offers non-invasive treatments for both therapeutic and aesthetic conditions using fluorescent light energy (FLE) to stimulate the skin’s own biological processes and repair mechanisms through photobiomodulation (PBM). Demonstrating high safety and efficacy, our technology triggers documented skin repairing benefits for a number of diseases and conditions. The company is headquartered in Dublin, Ireland, and builds on the scientific heritage from LEO Pharma and KLOX Technologies. Kleresca® is currently developing ten (10) markets including Australia, Italy, Spain, France, Switzerland, Germany, Belgium, Denmark, Norway and UK. Kleresca® is also registered as FB Dermatology.
Tags:
